Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2025)

China SXT Pharmaceuticals has reported Current Deferred Revenue over the past 8 years, most recently at $65057.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 65.82% year-over-year to $65057.0; the TTM value through Sep 2025 reached $65057.0, down 65.82%, while the annual FY2025 figure was $58627.0, 68.76% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $65057.0 at China SXT Pharmaceuticals, up from $58627.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $257449.0 in Q1 2021 and troughed at -$42994.0 in Q3 2021.
  • A 5-year average of $105933.0 and a median of $71233.5 in 2022 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 69.95% in 2022 and later skyrocketed 440.97% in 2024.
  • Year by year, Current Deferred Revenue stood at -$42994.0 in 2021, then soared by 251.42% to $65101.0 in 2022, then crashed by 45.95% to $35185.0 in 2023, then skyrocketed by 440.97% to $190340.0 in 2024, then plummeted by 65.82% to $65057.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for SXTC at $65057.0 in Q3 2025, $58627.0 in Q1 2025, and $190340.0 in Q3 2024.